- Conditions
- Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
- Interventions
- everolimus, bevacizumab
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab, Axitinib, Cabozantinib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • St Louis, Missouri + 5 more
- Conditions
- Coronary Artery Disease
- Interventions
- Ticagrelor 60mg, Clopidogrel
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Central Nervous System Tumors
- Interventions
- BLZ-100
- Drug
- Lead sponsor
- Blaze Bioscience Inc.
- Industry
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Facet-Mediated Low Back Pain, Lumbar Facet Joint Osteoarthritis
- Interventions
- BM-MSC injection, DSMO Injection
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Malignant Neoplasm, Solid Tumors
- Interventions
- Chloroquine, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Obesity, Overweight
- Interventions
- VRB-101, Placebo
- Drug
- Lead sponsor
- Verdiva Bio Dev Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 18 more
- Conditions
- Gynecologic Cancer
- Interventions
- Cesium-131 Low Dose Radiation (LDR)
- Device
- Lead sponsor
- Denise Fabian
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Healthy Volunteers
- Interventions
- [14C]-DZD9008
- Drug
- Lead sponsor
- Dizal Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Volunteers
- Interventions
- NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
- Drug
- Lead sponsor
- Marval Pharma Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
- Interventions
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 17 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, sargramostim, busulfan, carboplatin, cyclophosphamide, melphalan, paclitaxel, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- isoquercetin or quercetin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Parkinson's Disease
- Interventions
- Fipamezole ODT, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Torrance, California • Bingham Farms, Michigan • Willingboro, New Jersey + 1 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- AB-3028
- Biological
- Lead sponsor
- Arsenal Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 6 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- BRS201, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- HPV
- Interventions
- Gardasil-9, Lidocaine injection, Lorazepam
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Gram-negative Bacterial Infection
- Interventions
- Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Days to 88 Days
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- C.Surgical Procedure; Cardiac
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 1 Day to 6 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Schizophrenia
- Interventions
- DSP-1349M, placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
- Conditions
- Multiple Myeloma
- Interventions
- SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • Portland, Oregon
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- HY-0102
- Drug
- Lead sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Tyler, Texas
- Conditions
- Patients With Non-Small Cell Lung Cancer
- Interventions
- OSE2101, Docetaxel, NGS HLAA2 assay
- Drug · Device
- Lead sponsor
- OSE Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 79
- States / cities
- Beverly Hills, California • Encino, California • Los Angeles, California + 56 more